Molecular Formula | C22H18N6 |
Molar Mass | 366.42 |
Density | 1.27 |
Melting Point | 245℃ |
Boling Point | 634.1±65.0 °C(Predicted) |
Flash Point | 337.3°C |
Solubility | Acetone (Slightly), Chloroform (Slightly), DMSO (Slightly), Water (Very Slightly |
Vapor Presure | 5.56E-16mmHg at 25°C |
Appearance | Solid |
Color | Yellow |
pKa | 4.56±0.10(Predicted) |
Storage Condition | Refrigerator |
Refractive Index | 1.665 |
In vitro study | Rilpivirine exhibits antiviral activity against wild-type and selective site single and double HIV-1 mutants, with EC50 ranging from 0.1 nM to 2 nM. Rilpivirine inhibits viral replication, the first generation of NNRTIs does not inhibit the concentration of replication, and creates a high genetic barrier to hinder development. |
In vivo study | After intravenous injection of Rilpivirine, the elimination half-life ranges from 4.4 hours in rats to 31 hours in dogs. After oral administration of the PEG 400 of Rilpivirine, the Half-Life range is 2.8 Hours in rats and 39 hours in dogs. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.729 ml | 13.646 ml | 27.291 ml |
5 mM | 0.546 ml | 2.729 ml | 5.458 ml |
10 mM | 0.273 ml | 1.365 ml | 2.729 ml |
5 mM | 0.055 ml | 0.273 ml | 0.546 ml |
introduction | lipiavirin is a non-nucleoside reverse transcriptase inhibitor, usually used in combination with other antiretroviral drugs to treat human immunodeficiency virus (HIV) infection. The use of ribavirin may cause a short increase in serum aminotransferase in a few patients, and clinically obvious acute liver injury may occur in rare patients. |
biological activity | Rilpivirine (R278474, TMC27, DB08864) is a non-nucleoside reverse transcription inhibitor (NNRTI) and is used to treat HIV-1 infection. |
Target | Value |
toxic substance data | information provided by: pubchem.ncbi.nlm.nih.gov (external link) |